1. Home
  2. SG vs REPL Comparison

SG vs REPL Comparison

Compare SG & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sweetgreen Inc.

SG

Sweetgreen Inc.

HOLD

Current Price

$6.12

Market Cap

640.3M

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$6.22

Market Cap

692.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SG
REPL
Founded
2007
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
640.3M
692.8M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
SG
REPL
Price
$6.12
$6.22
Analyst Decision
Hold
Buy
Analyst Count
15
9
Target Price
$8.43
$11.00
AVG Volume (30 Days)
3.6M
2.4M
Earning Date
05-07-2026
05-21-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.25
EPS
N/A
N/A
Revenue
$679,474,000.00
N/A
Revenue This Year
$7.64
N/A
Revenue Next Year
$8.29
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.39
N/A
52 Week Low
$4.49
$2.68
52 Week High
$21.67
$13.24

Technical Indicators

Market Signals
Indicator
SG
REPL
Relative Strength Index (RSI) 60.84 29.54
Support Level $5.10 $4.39
Resistance Level $6.12 $4.95
Average True Range (ATR) 0.35 0.83
MACD 0.11 -0.23
Stochastic Oscillator 97.29 0.00

Price Performance

Historical Comparison
SG
REPL

About SG Sweetgreen Inc.

Sweetgreen Inc is a mission-driven, next-generation restaurant and lifestyle brand that serves healthy food at scale. Its bold vision is to be as ubiquitous as traditional fast food, but with the transparency and quality that consumers increasingly expect. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing. Its menu involves, Kids' meal, salads, sides, local items, Protein Plates, Desserts, Drinks and Others.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Share on Social Networks: